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Background: Huntington disease (HD) is an autosomal dominant neurodegenerative disorder, characterized by
motor, psychiatric and cognitive symptoms. HD is caused by a CAG repeat expansion in the first exon of the HTT
gene, resulting in an expanded polyglutamine tract at the N-terminus of the huntingtin protein. Typical disease
onset is around mid-life (adult-onset HD) whereas onset below 21 years is classified as juvenile HD. While much
research has been done on the underlying HD disease mechanisms, little is known about regulation and expression
levels of huntingtin RNA and protein.
Results: In this study we used 15 human post-mortem HD brain samples to investigate the expression of wild-type
and mutant huntingtin mRNA and protein. In adult-onset HD brain samples, there was a small but significantly lower
expression of mutant huntingtin mRNA compared to wild-type huntingtin mRNA, while wild-type and mutant
huntingtin protein expression levels did not differ significantly. Juvenile HD subjects did show a lower expression of
mutant huntingtin protein compared to wild-type huntingtin protein. Our results in HD brain and fibroblasts suggest
that protein aggregation does not affect levels of huntingtin RNA and protein. Additionally, we did not find any
evidence for a reduced expression of huntingtin antisense in fibroblasts derived from a homozygous HD patient.
Conclusions: We found small differences in allelic huntingtin mRNA levels in adult-onset HD brain, with significantly
lower mutant huntingtin mRNA levels. Wild-type and mutant huntingtin protein were not significantly different in
adult-onset HD brain samples. Conversely, in juvenile HD brain samples mutant huntingtin protein levels were lower
compared with wild-type huntingtin, showing subtle differences between juvenile HD and adult-onset HD. Since most
HD model systems harbor juvenile repeat expansions, our results suggest caution with the interpretation of huntingtin
mRNA and protein studies using HD cell and animal models with such long repeats. Furthermore, our huntingtin
antisense results in homozygous HD cells do not support reduced huntingtin antisense expression due to an expanded
CAG repeat.
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Huntington disease (HD) is an autosomal dominant neu-
rodegenerative disorder, characterized by motor, psychi-
atric and cognitive symptoms [1]. HD is caused by a
CAG repeat expansion in the first exon of the HTT gene
on chromosome 4p16, resulting in an expanded polyglu-
tamine (polyQ) tract at the N-terminus of the huntingtin* Correspondence: w.vanroon@lumc.nl
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unless otherwise stated.(htt) protein. People carrying 40 or more CAG repeats
will develop HD, whereas people with 36 to 39 repeats
show reduced penetrance [2,3]. The mean disease onset
lies between 30 and 50 years of age (adult-onset HD).
HD patients carrying more than 50 CAGs will have a
disease onset typically below 21 years of age (juvenile
HD) [1]. The major neuropathology in HD occurs in the
striatum and cerebral cortex but degeneration is seen
throughout the brain as the disease progresses [4] and
insoluble protein aggregates in the nucleus and cyto-
plasm of cells are a hallmark of the disease [5].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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expression is limited and inconsistent. In patient-derived
lymphoblasts, no CAG repeat-related effect on total
HTT mRNA was observed [6], suggesting that there is
no difference in wild-type and mutant HTT RNA ex-
pression. On the other hand, upregulation of mutant
HTT mRNA translation in HD was suggested by inter-
action of the expanded CAG repeat with the MID1-
PP2A complex [7]. Upregulation of mutant HTT mRNA
translation was also suggested by HTT antisense tran-
script regulation [8]. Two natural HTT antisense tran-
scripts (HTTAS) were identified at the HTT locus, of
which one HTTAS contains a CTG repeat. Overexpres-
sion of HTTAS resulted in reduced HTT transcript
levels, whereas knockdown increased HTT transcript
levels [8]. Furthermore, in post-mortem HD brain no
HTTAS with an expanded CTG repeat could be de-
tected. From these observations, it was suggested that
HTTAS negatively regulated HTT transcript expression
and that loss of HTTAS in HD increases mutant HTT
mRNA levels [8]. Upregulation of mutant HTT mRNA
in human post-mortem HD brain tissue was confirmed
recently using an allele-specific quantitative (q)PCR [9].
However, endogenous mRNA expression levels have not
been related to subsequent mutant and wild-type htt
protein levels. Also the effect of the presence of insol-
uble protein aggregates on htt protein levels is not
known.
In this study we have examined HTT mRNA and htt
protein levels in HD patient-derived fibroblasts and
post-mortem brain tissue with varying CAG repeat
lengths. We find a decrease in mutant HTT mRNA
levels compared to wild-type in adult-onset HD patients.
However, this reduced mutant HTT mRNA expression
did not result in lower mutant htt protein levels. In con-
trast, juvenile HD fibroblasts and brain tissue did show
lower levels of mutant htt protein compared to wild-
type htt protein, indicating subtle differences in htt pro-
tein expression between adult-onset and juvenile HD.
Results
Validation of RT-PCR amplification across the CAG repeat
To reliably measure both wild-type and mutant HTT
mRNA we first optimized our PCR procedure to account
for differences in amplification across the CAG repeat
expansion. To exclude amplification bias across the
CAG repeat in our PCR [10], we fitted a linear regres-
sion curve of both wild-type and mutant HTT genomic
DNA (gDNA) with increasing PCR cycles (Figure 1A).
PCR linearity was evaluated by determining the linear
regression coefficient (r2) of the band intensities versus
the number of PCR cycles. Both wild-type and mutant
PCR products showed a linear increase in gel electro-
phoresis band intensity with increasing PCR cyclenumber (wild-type, r2 = 0.8680; mutant, r2 = 0.8282). The
slopes were not significantly different (P = 0.6485), indi-
cating that the PCR was equally efficient for both wild-
type and mutant HTT. Additionally, we always used
gDNA as a reference since gDNA has a 1:1 ratio of nor-
mal and expanded HTT. Next, we performed RT-PCR
expansion across the CAG repeat using four adult-onset
HD patient-derived fibroblasts (Figure 1B). Reverse tran-
scription without reverse transcription enzyme was
taken along, verifying that there was no gDNA contam-
ination in our RT-PCR (Figure 1C). For each fibroblast
line the two PCR products corresponding to wild-type
and mutant HTT mRNA were quantified and average
expression levels of wild-type and mutant HTT mRNA cal-
culated (Figure 1D). No significant difference (P = 0.7642)
between wild-type and mutant HTT mRNA expression
was observed in adult-onset HD patient-derived fibroblasts.
Less mutant HTT mRNA in human post-mortem HD brain
material
Next, we investigated HTT mRNA expression levels in
post-mortem brain tissue from HD patients with a wide
range of repeat lengths. RNA and gDNA was isolated from
frontal cortex or middle temporal gyrus and PCR was per-
formed with primers flanking the CAG repeat (Figure 2A).
The wild-type and mutant PCR products for each brain
sample were quantified and normalized against PCR prod-
ucts from gDNA and individual wild-type versus mutant
HTT mRNA expression levels were calculated. Next, the
average expression levels of wild-type and mutant HTT
mRNA in the frontal cortex (Figure 2B) and middle tem-
poral gyrus (Figure 2C) of adult-onset HD patients were
calculated. We found a significant 31.0% (SEM± 6.1%)
lower average mutant HTT mRNA compared to wild-type
HTT mRNA expression in the frontal cortex from HD
patients. In the middle temporal gyrus, a 22.1% (SEM±
10.9%) lower average mutant HTT mRNA expression was
found. When we combined all the brain samples and
repeated the analysis we found a significant lower average
mutant HTT mRNA expression of 26.6% (SEM± 6.1%)
compared to wild-type HTT mRNA (Figure 3A).
To validate our results with a different technique, we
performed a single nucleotide polymorphism (SNP)-spe-
cific TaqMan qPCR, using probes for rs362273 SNP
located at on the 3′ side of HTT in exon 57. Of our
post-mortem brain samples, 6 out of 14 were heterozy-
gous for rs362273. Next, SNP linkage by circularization
(SLiC) [11] was performed to determine which allele has
the guanine and which allele the adenine in exon 57.
Due to the variable RNA quality of brain tissue, SLiC
was only possible in 4 out of 6 samples. TaqMan qPCR
showed an identical trend towards more wild-type HTT
as was found for our RT-PCR analysis (Figure 3B), but
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Figure 1 Validating RT-PCR amplification across the CAG repeat in HD patient-derived fibroblasts. Wild-type and mutant HTT were separated by
gel electrophoresis. (A) Standard curve of wild-type and mutant HTT RT-PCR products with increasing PCR cycles from gDNA derived from
post-mortem brain tissue of 7 HD patients. PCR linearity was evaluated by determining the individual linear regression coefficients (r2) of the band
intensities of wild-type and mutant HTT expression versus the number of PCR cycles, n = 7. (B) PCR products from cDNA of 4 HD (GM00305,
GM02173, GM04022, GM04855) fibroblasts. CAG repeat sizes for the wild-type (lower band) and mutant alleles (upper band) are indicated below
each lane. gDNA was used to examine differences in PCR amplification between the wild-type and mutant product due to the CAG repeat
expansion. (C) RT-PCR products with input: cDNA (+RT), cDNA lacking reverse transcriptase (−RT) and gDNA of one control (GM04204). (D) Whisker
boxplot of RT-PCR from HD patient-derived fibroblasts, comparing wild-type and mutant HTT mRNA expression levels, relative to gDNA. Line =mean,
pair wise differences were evaluated using linear mixed model, n = 4.
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fication across the CAG repeat is an accurate technique to
measure small allelic differences in mRNA expression.
Despite a lower RNA quality in our juvenile HD sam-
ples compared to the adult-onset HD samples, we were
able to separate both alleles by amplification across the
CAG repeat in cDNA and gDNA samples (Figure 4A).
Consistent with adult-onset HD samples, we found a
22.6% (SEM± 10.6%) lower mutant HTT mRNA expres-
sion compared to wild-type HTT mRNA in post-mortem
brain tissue from juvenile HD patients (Figure 4B).
No difference in wild-type and mutant htt protein levels
in adult-onset HD
To relate the observed differences in allelic HTT mRNA
expression to wild-type and mutant htt protein levels,
we analyzed SDS-soluble htt protein levels in both HD
fibroblasts (Figure 5A) and post-mortem human HD
brain homogenates (Figure 5B) using Western blot.
Wild-type and mutant htt protein bands were quantified
and both the individual wild-type and mutant htt protein
levels were calculated as well as the average of all indi-
vidual measurements. No significant difference betweenwild-type and mutant htt protein levels in patient-
derived fibroblasts was found (Figure 5C). Likewise, in
the post-mortem human HD brain homogenates there
was no difference in wild-type and mutant htt protein
levels (Figure 5D).
It is known that in post-mortem human HD brain,
mutant htt aggregates in a polyQ length-dependent
manner [12], while no mutant htt aggregates are present
in HD patient-derived fibroblasts [13]. Our results show
that the levels of soluble wild-type and mutant htt pro-
tein do not change in the absence or presence of htt
protein aggregates.
Less mutant than wild-type htt protein in juvenile HD
Next, we analyzed SDS-soluble wild-type and mutant htt
levels in juvenile HD samples. Htt protein levels from
patient-derived fibroblasts with mutant polyQ lengths of
73, 99 and 181 were analyzed onWestern blot (Figure 6A).
Juvenile HD fibroblast lysates showed a significant 10.1%
(SEM± 2.7%) lower level of mutant htt protein compared
to wild-type htt (Figure 6B).
Next, we analyzed SDS-soluble levels of wild-type and






































































































































Figure 2 Wild-type and mutant HTT mRNA levels in adult-onset HD brain tissue. Wild-type and mutant HTT mRNA PCR products were separated
on gel electrophoresis by differences in their CAG repeat length. (A) RT-PCR products from brain tissue derived from a control (H121) and 10 HD
patients. Allelic CAG repeat sizes are indicated below each lane. gDNA from each sample was taken along to control for differences in PCR
amplification efficiencies across the CAG repeat. (B) Whisker boxplot of allelic HTT mRNA expression levels in frontal cortex from 5 HD adult-onset
HD patients. (C) Whisker boxplot of allelic HTT mRNA expression levels in middle temporal gyrus from 5 HD adult-onset HD patients. Expression
levels relative to gDNA. Pair wise differences were evaluated using linear mixed model, n = 5.
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multiple mutant htt protein products (Figure 6C). Despite
of the reduced quality of the post-mortem juvenile HD
brain lysates, we were able to quantify the protein bands
and showed 16.4% (SEM± 7.0%) lower mutant htt protein
levels with respect to wild-type htt (Figure 6D).
These results show that in adult-onset HD samples, wild-
type and mutant htt protein levels are equal, regardless ofA RT-PCR
































Figure 3 HTT mRNA quantification after RT-PCR amplification across the CAG
of wild-type versus mutant HTT mRNA expression levels in adult-onset HD po
CAG repeat, relative to gDNA. Pair wise differences were evaluated using linea
normalized to β-actin (ACTB). Data were evaluated using a two-tailed studentmutant htt protein aggregation. In juvenile HD there is a
consistent lower level of mutant htt protein expression.
HTT antisense expression in HD patient-derived fibroblasts
and post-mortem brain tissue
It is known that a lower expression of HTTAS that contains
the CTG repeat can increase HTT mRNA expression [8].


































repeat compared to SNP-specific quantitative RT-PCR. Whisker boxplots
st-mortem brain material. (A) Quantification after amplification across the
r mixed model, n = 10. (B) SNP rs362273-specific quantitative RT-PCR,

























































Figure 4 Wild-type and mutant HTT mRNA levels in juvenile HD brain. Wild-type and mutant HTT mRNA PCR products were separated by gel
electrophoresis. (A) RT-PCR products from brain tissue derived from two juvenile HD patients (HD192 and HC104). CAG repeat sizes for the
wild-type and mutant alleles are indicated below each lane. gDNA was used to control for differences in PCR amplification between the
wild-type and mutant product due to the CAG repeat expansion. (B) Whisker box plot comparing wild-type and mutant HTT mRNA expression
levels, relative to gDNA. Pair wise differences were evaluated using linear mixed model, n = 4.
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gated HTTAS expression in fibroblasts and post-mortem
brain tissue from HD patients. In post-mortem brain tissue
we detected comparable levels of HTTAS in HD and con-
trol brain tissue (Figure 7A). We could also reliably detect
HTTAS in all cell lines that we investigated, including the
homozygous HD patient-derived fibroblasts (Figure 7B).
Sanger sequencing confirmed that this was HTTAS with
the expanded CTG repeat. This was unexpected since re-
duced expression of HTTAS with an expanded CTG repeat
was reported in post-mortem HD brain [8], which would
suggest no expression of this HTTAS when both HTT
alleles contain an expanded repeat. We conclude that our
























































Figure 5 Wild-type and mutant htt protein levels in HD fibroblasts and bra
fibroblasts from three HD patients (GM02173, GM04022, GM04855). The low
repeat lengths are indicated below each lane. (B) Western blot analysis of
comparing wild-type and mutant htt levels normalized against total htt in
wise differences were evaluated using linear mixed model.levels in post-mortem brain are probably not caused by
altered transcription of HTTAS with an expanded CTG
repeat.
Discussion
In the current study we found that in post-mortem
adult-onset HD brain material the levels of wild-type
and mutant HTT mRNA were significantly different. We
found lower levels of mutant HTT mRNA compared to
wild-type in the frontal cortex and a trend towards lower
mutant HTT mRNA levels in the middle temporal gyrus.
In adult-onset HD patient-derived fibroblasts the levels
of wild-type and mutant HTT mRNA did not differ.

























































in tissue. (A) Western blot analysis of total protein lysates from human
er band represents wild-type htt, the upper band mutant htt. PolyQ
cortical brain homogenates from six HD subjects. (C) Whisker box plots
HD fibroblasts (n = 3) and (D) post-mortem brain tissue (n = 6). Pair
juvenile HD brains

































































































Figure 6 Wild-type and mutant htt protein levels in juvenile HD fibroblasts and brain tissue. (A) Western blot analysis of total protein lysates
from human fibroblasts derived from three juvenile HD subjects (GM04281, GM05539, GM09197). The lower band represents wild-type htt, the
upper band mutant htt. PolyQ repeat lengths are indicated below each lane. (B) Whisker box plot comparing wild-type and mutant htt levels
normalized against total htt in juvenile HD fibroblasts (n = 3). (C) Post-mortem cortical brain tissue from four juvenile HD subjects (HD192, HC104,
HD86, HD29). (D) Whisker box plot comparing wild-type and mutant htt levels normalized against total htt in juvenile HD post-mortem brain
tissue (n = 4). Pair wise differences were evaluated using linear mixed model.
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expanded CAG repeat did not affect HTT mRNA
expression [6]. Conversely, a small (~10%) upregulation
of mutant HTT mRNA was recently shown in human
post-mortem HD brain tissue using SNP-specific qPCR
[9]. These contradictory results could be explained by
the fact that the two SNP’s used in this study were both
located outside HTT Exon 1 (3′UTR, and Exon 50). Fur-
thermore, the small upregulation of mutant HTT mRNA
was most pronounced in post-mortem brain material de-
rived from patients with early neuropathological grades
(grades 1 and 2), whereas the material in our study was
generally of later disease stages (grades 3 and 4).
Wild-type and mutant htt protein levels did not signifi-
cantly differ in either fibroblasts or post-mortem brain sam-
ples of adult-onset HD patients. Soluble htt has a half-life
of approximately 24 hours [14] and we hypothesize that
with Western blot analysis we detect soluble htt that is
present in the cells. Protein aggregation is an important
feature in HD brain tissue, but does not occur in HD fibro-
blasts [13], our results show that protein aggregation does
not affect the levels of soluble htt protein. However, we did
find lower mutant HTT mRNA levels in brain. A possible
explanation could be an enhanced translation of mutant
HTT mRNA, resulting in equal htt protein levels. Recently,
increased translation of mutant HTT was suggested [7].Cells overexpressing N-terminal htt fragments with a nor-
mal and mutant polyQ repeat showed an enhanced protein
synthesis of htt fragments with an expanded polyQ repeat.
This more efficient translation of mutant HTT mRNA was
proposed to be caused by enhanced binding of the MID1-
complex to the expanded CAG repeat and mediated by
mTOR and S6K kinases [7].
Two of the three juvenile HD brain lysates showed
multiple mutant htt protein products. This could be due
to somatic mosaicism of mutant htt in the brain of
juvenile patients [15] or due to reduced protein quality
caused by the post-mortem delay. These multiple mu-
tant htt protein products were not present in the fibro-
blast samples. Nonetheless, we consistently, found that
the levels of mutant htt protein were lower than wild-
type in both fibroblasts and post-mortem brain tissue of
juvenile HD patients. This is in contradiction with previ-
ous studies in knock-in HD mice carrying one or two al-
leles with 111 CAG repeats [7], which showed increased
mutant htt protein levels. The lower mutant htt protein
level in juvenile HD is consistent with lower levels of
mutant HTT mRNA. Although juvenile HD is much
rarer than adult-onset HD [16], for development of a
rapid phenotype HD animal models generally carry a
mutant HTT transgene with juvenile CAG repeats [17].
























































Figure 7 HTT antisense expression in HD patient-derived fibroblasts and
brain tissue. Gel electrophoresis of HTTAS amplified using strand- and
HTTAS isoform-specific primers. (A) RT-PCR of patient-derived fibroblasts
from a control (GM04204), an HD patient (GM02173), an HD patient
homozygous for the CAG repeat expansion (GM04857) and a juvenile
HD patient (GM05539). (B) RT-PCR of post-mortem brain tissue from a
control (H121), an HD patient (HC105), and 2 juvenile HD patients
(HD192 and HD86). Allelic CAG repeat sizes below each lane.
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brain samples and this should be taken into account when
interpreting results from HD models carrying a juvenile
repeat expansion.
Recently it has been suggested that in polyQ disorders
bidirectional RNA transcription could play a role in the
disease pathology by deregulation of the sense transcript
[8,18]. It was hypothesized that a bidirectional RNA tran-
script called HTTAS, negatively regulates htt transcript
expression [8]. In accordance, in HD patient-derived fibro-
blasts and brains HTTAS with the expanded CTG repeat
could not be detected [8]. Our results show HTTAS
expression in all HD samples and most notably in patient-
derived fibroblasts homozygous for the CAG repeat
expansion, suggesting that there is an HTTAS with ex-
panded CTG repeat transcribed. We can conclude how-
ever that differences in allelic HTT transcript levels in
post-mortem brain are probably not caused by lower levels
of HTTAS.Recent advances have shown the potential of reducing
mutant htt levels with oligonucleotide-based therapeutics.
Reduction of both wild-type and mutant htt up to 70% was
well tolerated in HD rodent models and non-human pri-
mates [19]. Long-term suppression of wild-type and mutant
htt might not be desirable because of htt’s anti-apoptotic
function [20] and importance for cell survival in the adult
brain [21,22]. A different approach would be an allele-
specific reduction of mutant htt. This could be achieved
with oligonucleotides directed against SNPs unique to the
mutant htt transcript, or by targeting the expanded CAG
repeat directly [23]. Although our allelic HTT mRNA ex-
pression levels are in disagreement to that of Liu et al. [9],
the overall differences in basal HTT mRNA in both studies
are small. This shows that the levels of wild-type and mu-
tant htt protein are not considerably different and provides
feasibility for oligonucleotide therapeutics that are not com-
pletely specific for the mutant HTT allele.Conclusions
Although we found significantly lower mutant HTT
mRNA levels in adult-onset HD, wild-type and mutant htt
protein levels did not differ significantly in adult-onset HD
brain samples. Conversely, in juvenile HD brain samples
mutant htt protein levels were lower compared with wild-
type htt, showing subtle differences between juvenile HD
and adult-onset HD. Since most HD model systems har-
bor juvenile repeat expansions, our results suggest caution
with the interpretation of htt mRNA and protein studies
using HD cell and animal models with such long repeats.
Furthermore, our HTTAS results in homozygous HD cells
do not support reduced HTTAS expression due to an
expanded CAG repeat.Methods
Patient-derived fibroblasts and human brain samples
Fibroblasts derived from HD patients and controls
were purchased from Coriell Cell Repositories, Camden,
USA (Table 1). Fibroblasts were cultured at 37°C and 5%
CO2 in Minimal Essential Medium (Gibco Invitrogen,
Carlsbad, USA) with 15% heat inactivated Fetal Bovine
Serum (Clontech, Palo Alto USA), 1% Glutamax (Gibco)
and 100 U/ml penicillin/streptomycin (Gibco).
Post-mortem human brain tissue was obtained from
the Neurological Foundation of New Zealand Human
Brain Bank in the Centre for Brain Research, University
of Auckland, and the brain bank from the department of
Neurology, Leiden University Medical Center. Tissue
was obtained with the families full consent and with the
ethical approval of the various institutional Ethics Com-
mittees. For a complete list of samples and correspond-
ing clinical information, see Table 2.
Table 1 Patient-derived fibroblasts
Name CAG 1 CAG 2 Type Age at sampling Age of onset Sex
GM00305 42 15 HD 56 46 F
GM02173 44 17 HD 52 NA F
GM04022 44 18 HD 28 NA F
GM04855 48 20 HD 11 26 M
GM04857 50 40 Homozygous HD 23 28 F
GM04281 71 17 Juvenile HD 20 14 F
GM05539 97 22 Juvenile HD 10 2 M
GM09197 179 18 Juvenile HD 6 NA M
GM04204 18 17 Control 81 NA M
M: male, F: female, NA: not assessed.
Samples ranked on CAG repeat size of the longest allele.
Evers et al. Molecular Neurodegeneration  (2015) 10:21 Page 8 of 11CAG repeat sizing
Genomic DNA samples were isolated from patient-
derived fibroblasts and human brain using the Wizard
Genomic DNA Purification Kit (Promega, Madison,
USA) according to manufacturer’s instructions and
diluted to 50 μg/ml. The number of CAG repeats in
the HTT gene was determined by PCR using primers
“HD-1” and “HD-3” as described previously [24],
followed by fragment analysis on an ABI 3130 Auto-
mated Capillary DNA Sequencer (Applied Biosystems,
Life Technologies Corporation, Carlsbad, USA). The
exact PCR conditions are available on request. The 3′
CAA and following CAG are not counted. For the
polyQ repeat the CAA and CAG triplet are counted
and the polyQ repeat is therefore 2 units longer than
the CAG repeat size.Table 2 Post-mortem human brain tissue
Name CAG 1 CAG 2 Type Tissue P
HC103 40 19 HD MTG 1
HC105 42 15 HD MTG 9
HD166 42 17 HD FC 3
HC102 43 17 HD MTG 1
HC107 43 19 HD MTG 3
HD193 44 9 HD FC 1
HD188 44 16 HD FC N
HD195 44 22 HD FC 8
HD159 47 17 HD FC 4
HC114 47 21 HD MTG 1
HD192 52 18 Juvenile HD FC 6
HC104 53 18 Juvenile HD MTG 1
HD86 84 17 Juvenile HD FC 2
HD29 84 20 Juvenile HD FC 1
H121 23 18 Control MTG 6
MTG: middle temporal gyrus, FC: frontal cortex, PMD: post-mortem delay (hours), G
Samples ranked on CAG repeat size of the longest allele.RNA and genomic DNA analysis
Post-mortem brain tissue was homogenized using cer-
amic MagNA Lyser beads (Roche, Mannheim, Germany)
by grinding in a Bullet Blender (Next Advance, Averill
Park, USA) according to manufacturer’s instructions.
Total RNA was isolated from fibroblast cells and brain
tissue using the Aurum Total RNA Mini Kit (BioRad,
Hercules, USA), with an on-column DNase treatment
for 30 min. RNA was eluted in 40 μl elution buffer and
cDNA was synthesized from 1 μg total RNA using the
Transcriptor First Strand cDNA Synthesis Kit with oligo
(dT) primers at 55°C for 90 min (Roche).
PCR was performed using 1 μl cDNA or genomic DNA,
10x Expand High Fidelity buffer with 15 mM MgCl2
(Roche), 200 μM dNTPs (Roche), 1 M Betaine (Sigma-
Aldrich, St. Louis, USA), 15 pmol of both forward primerMD Grade Age of death Age of onset Sex
1 1 41 35 M
1 67 47 F
2 2 80 >70 M
0 3 64 40 M
3 75 58 M
8 3 68 44 M
A 3 64 44 M
.5 3 61 NA F
2 3 41 26 F
2 NA 53 30 F
2 4 37 NA M
5 3 40 15 M
0 3 20 16 F
1 NA 11 8 F
control 64 control F
rade: neuropathological classification [28], M: male, F: female, NA: not assessed.
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AT-3′ and reverse primer HttCAGRev: 5′-TGA GGC
AGC AGC GGC TG-3′ (Eurogentec, Liege, Belgium), 3 U
Expand High Fidelity enzyme mix (Roche), and PCR grade
water to a final volume of 30 μl. The PCR program started
with a 2 min initial denaturation at 94°C, followed by
35 cycles of 15 sec denaturation at 94°C, 30 sec annealing
at 60°C, 1 min elongation at 72°C, and final elongation
step at 72°C for 7 min.
PCR products were loaded on a 2% agarose gel diluted
in Tris/Borate/EDTA (TBE) buffer. DNA gel electro-
phoresis was performed for 1 hour at 100 V. Intensities
of DNA bands were quantified using ImageJ software.
Intensity of the HTT mRNA band was divided by the
corresponding genomic DNA band to normalize for
differences in PCR efficiency due to CAG repeat length.
SNP genotyping and SNP linkage by circularization (SLiC)
The procedure for SNPs rs362273 genotyping and SNP
linkage by circularization on human brain tissue was
adapted from Liu et al. [11]. One μg of DNase-treated
total RNA, together with oligo (dT) primers, was used
for cDNA synthesis using SuperScript III First-Strand
Synthesis System (Invitrogen). To improve reverse tran-
scription of long cDNA templates, 2 M betaine and
0.6 M trehalose (both Sigma-Aldrich) were added to the
reaction mixture [25]. cDNA synthesis was performed at
42°C for 2.5 hours, followed by RNase H treatment at
37°C for 20 min. Next, 5 μl cDNA was used as template
for long-range PCR and SLiC.
Taqman SNP assay
Quantitative PCR was performed using the LightCycler
480 II (Roche), according to manufacturer’s instructions,
using a mixture containing 45 ng cDNA, 1xTaqMan
Universal PCR Master Mix, no AmpErase UNG (Ap-
plied Biosystems), 1xTaqMan SNP Genotyping Assay
(Applied Biosystems), and nuclease-free water (Ambion)
in a 20 μl reaction volume. ACTB (Applied Biosystems,
cat#Hs99999903_m1) was included as reference gene. A
standard curve was generated using pooled equal amounts
of cDNA from all samples. Quantification of the dual-
color hydrolysis of both allele-specific fluorescent re-
porter dyes, FAM (“G” allele) and VIC (“A” allele),
was performed with the LightCycler 480 SW 1.5.1
software (Roche) using the 2nd derivative method, ac-
cording to manufacturer’s instructions.
HTT antisense determination
RNA isolation as described above. PCR was performed
using 1.5 μl cDNA, 10x PCR buffer with 20 mM MgCl2
(Roche), 200 μM dNTPs (Roche), 6 pmol HTTAS_v1
primer, forward: 5′-CAC CGG GGC AAT GAA TGG-
3′, reverse: 5′-GTG CGG ATG GCA AGG ACA G-3′,2 U FastStart Taq DNA Polymerase (Roche), 1 M ethylene
glycol (Sigma-Aldrich), and PCR grade water to a final
volume of 30 μl. The PCR program started with a 3 min
initial denaturation at 95°C, followed by 40 cycles of
10 sec denaturation at 95°C, 10 sec annealing at 60°C,
10 sec elongation at 72°C, after which a final elongation
step was performed at 72°C for 7 min.
PCR products were loaded on a 3% TBE agarose gel
and bands were extracted using the NucleoSpin Gel &
PCR Clean-up kit (Machery Nagel, Düren, Germany).
To confirm the sequence of HTTAS, PCR products were
cloned into a pGEM-T Easy vector (Promega) and ana-
lyzed by Sanger sequencing using a T7-specific forward
primer.
Protein isolation
Fibroblasts were detached from the culture surface with
a 0.5% Trypsin/EDTA solution. After washing twice with
HBSS, cells were resuspended in 200 μl ice cold lysis buffer,
containing 50 mM HEPES, 50 mM NaCl, 10 mM EDTA,
10 mM DTT, 0.1% CHAPS, and 1 tablet Complete mini
protease inhibitor EDTA free (Roche) per 10 ml buffer [26].
Next, samples were sonicated 3 times 5 sec using ultra-
sound with amplitude 60 at 4°C. After 1 hour head-over-
head incubation at 4°C, extracts were centrifuged for
15 min at 10,000 × g and 4°C and supernatant was isolated.
For brain homogenates, slices from frozen unfixed
human brain tissue were collected using a sliding micro-
tome (Leica SM 2010R). Tissue was homogenized using
ceramic MagNA Lyser beads (Roche) by grinding in a
Bullet Blender (Next Advance) for 3 min at strength 8 in
lysis buffer with pH 7.2, containing 1% CHAPS, 137 mM
NaCl, 2.7 mM KCl, 4.3 mM Na2PO4, 1.4 mM KH2PO4,
5 mM EDTA, 5 mM EGTA, and 1 tablet Complete mini
protease inhibitor EDTA free (Roche) per 10 ml buffer
[27]. Homogenates were incubated for 1 hour in a head-
over-head rotator at 4°C, and centrifuged for 15 min at
10,000 × g at 4°C.
Protein concentrations were determined with the
bicinchoninic acid kit (BCA) (Thermo Fisher Scientific,
Waltham, USA) using Bovine Serum Albumin (BSA) as
a standard. After addition of 5% glycerol, samples were
aliquotted, snap frozen and stored at −80°C.
Western blotting
SDS-PAGE separation of proteins was performed ac-
cording to the “shorter CAG repeats” protocol as de-
scribed previously [27]. Proteins were transferred to a
0.2 μm nitrocellulose membrane (Bio-Rad, #170-4159)
using the Trans-blot Turbo (BioRad) at 2.5A (constant)/
25 V for 10 min. Membranes were blocked for 15 min in
tris buffered saline containing 5% non-fat milk (Nutricia,
Schiphol, the Netherlands). Next, membranes were incu-
bated with primary rabbit antibody EPR5526 (Abcam,
Evers et al. Molecular Neurodegeneration  (2015) 10:21 Page 10 of 11Cambridge, UK) that recognizes the N-terminus of the
htt protein, diluted 1:5000 in blocking buffer, followed
by secondary incubation with rabbit IRDye800 (LI-COR,
Lincoln, USA) diluted 1:5000 in blocking buffer. Blots
were analyzed on an Odyssey reader (LI-COR). Protein
bands corresponding to were quantified using the
Odyssey software version 3.0 (LI-COR). Background cor-
rection was performed by sampling an empty area of the
blot of the same size as the area that contained the posi-
tive protein band. Quantification of wild-type and mu-
tant htt protein relied on densitometry measurement of
both western blot bands separately. In case separation
was small, we could magnify our scanned blots using the
software’s “zoom” function to aid in a proper alignment
of the densitometry calculation boxes over both separate
bands. Wild-type and mutant htt protein expression
levels relative to total htt protein expression were calcu-
lated by dividing wild-type and mutant htt band inten-
sities with total htt band intensity (wild type +mutant).
Statistical analyses
Experiments were performed at least six times per sub-
ject (3 biological and 2 technical replicates). PCR linear-
ity was evaluated by GraphPad Prism version 6.02 by
determining the individual linear regression coefficients
(r2) of the band intensities of wild-type and mutant
HTT expression versus the number of PCR cycles.
GraphPad Prism version 6.02 was used to create whis-
ker boxplots (whiskers =min to max), showing all mean
values per sample. IBM SPSS Statistics Version 20.0.0
was used for statistical analysis. All datasets were tested
for a Gaussian distribution by visual inspection after
plotting the residuals. Significance of the pairwise differ-
ences was determined using a linear mixed model.
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